Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27337917 | 0.78 | ALDH1A1 (0.47) | HTTKMT2AMEN1SCN2AKAT2B | |
| SCHEMBL77918 | 0.75 | MAPT (0.48) | CYP19A1HTTKMT2AMEN1MAPT | |
| SCHEMBL8266914 | 0.75 | F2 (0.42) | CYP19A1HTTKMT2AMEN1MAPT | |
| SCHEMBL16361758 | 0.74 | SMN1; SMN2 (0.46) | HTTKMT2AMEN1KAT2BMAPT | |
| SCHEMBL85578 | 0.74 | SCN2A (0.54) | HTTKMT2AMEN1SCN2AKAT2B | |
| SCHEMBL7557950 | 0.73 | MEN1 (0.45) | CYP19A1HTTKMT2AMEN1SCN2A | |
| SCHEMBL17743745 | 0.73 | MEN1 (0.45) | CYP19A1HTTKMT2AMEN1SCN2A | |
| SCHEMBL9402020 | 0.73 | KMT2A (0.45) | CYP19A1HTTKMT2AMEN1KAT2B | |
| SCHEMBL2048930 | 0.73 | ALDH1A1 (0.57) | CYP19A1HTTKMT2AMEN1MAPT | |
| SCHEMBL5390679 | 0.73 | MAPT (0.47) | CDC7HTTKMT2AMEN1SCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087582-A1 | Phenyl derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2004-05-06 | — | — | US | claimed |
| EP-1351938-A1 | PHENYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002057236-A1 | PHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-07-25 | — | — | WO | claimed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| EP-1636216-B1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-07-21 | — | — | EP | disclosed |
| US-7741341-B2 | Benzimidazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-22 | — | — | US | disclosed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | disclosed |
| EP-1571154-A1 | Beta-aminoacid-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101553-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004087646-A2 | PYRROLIDINO-1,2-DICARBOXY-1-(PHENYLAMIDE)-2-(4-(3-OXO-MORPHOLINO-4-YL)-PHENYLAMIDE) DERIVATIVES AND RELATED COMPOUNDS FOR USE AS INHIBITORS OF COAGULATION FACTOR XA IN THE TREATMENT OF THROMBO-EMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087696-A1 | PYRAZOLIDINE-1,2-DICARBOXYLDIPHENYLAMIDE DERIVATIVES AS COAGULATION FACTOR XA INHIBITORS FOR THE TREATMENT OF THROMBOSES | MERCK PATENT GMBH (DE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004046138-A1 | CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2004-06-03 | — | — | WO | disclosed |
| US-20040087582-A1 | Phenyl derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2004-05-06 | — | — | US | disclosed |
| WO-2004035039-A1 | HETEROCYCLIC AMIDES AND THEIR USE IN TREATING THROMBOEMBOLIC DISEASES AND TUMORS | MERCK PATENT GMBH (DE) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | CDC7 1742/4885CYP19A1 321/4885HTT 3853/4885 |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | F12, F11, F5 | CDC7 2816/4885CYP19A1 552/4885HTT 4238/4885 |
| US-20040087582-A1 | Phenyl derivatives | F2, F11, SERPINC1 | CDC7 4097/4885CYP19A1 564/4885HTT 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.